Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...

It was there that Mr Pearce, 40, was diagnosed with a branch retinal vein occlusion, where one of the veins in the retina ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

Then doctors examined her. Her right eye looked normal, but doctors saw a transient central retinal artery occlusion — a vessel blockage — in her left eye. Central retinal artery occlusions ...

A total of two patients with remote preoperative branch retinal artery occlusion ... such as diabetic retinopathy and retinal vein occlusion (12–14). In this study, we found significantly decreased ...

"We have been able to demonstrate that Ziapin2 can regenerate the physiological antagonism between the ON retinal neurons, which signal the presence of light, and the OFF neurons, which signal the ...

The injuries just keep on coming for the Detroit Lions in the divisional round game against the Washington Commanders, as safety Brian Branch is the latest player to come down with an issue.